Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Bioequivalence Comparison of Pediatric Dasatinib Formulations and Elucidation of Absorption Mechanisms Through Integrated PBPK Modeling.

Vaidhyanathan S, Wang X, Crison J, Varia S, Gao JZH, Saxena A, Good D.

J Pharm Sci. 2019 Jan;108(1):741-749. doi: 10.1016/j.xphs.2018.11.005. Epub 2018 Nov 13.

PMID:
30439460
2.

Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?

Gampa G, Vaidhyanathan S, Sarkaria JN, Elmquist WF.

Pharmacol Res. 2017 Sep;123:10-25. doi: 10.1016/j.phrs.2017.06.008. Epub 2017 Jun 17.

3.

Challenges in the delivery of therapies to melanoma brain metastases.

Gampa G, Vaidhyanathan S, Resman BW, Parrish KE, Markovic SN, Sarkaria JN, Elmquist WF.

Curr Pharmacol Rep. 2016 Dec;2(6):309-325. doi: 10.1007/s40495-016-0072-z. Epub 2016 Nov 9.

4.

Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases.

Vaidhyanathan S, Wilken-Resman B, Ma DJ, Parrish KE, Mittapalli RK, Carlson BL, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2016 Feb;356(2):251-9. doi: 10.1124/jpet.115.229393. Epub 2015 Nov 24.

5.

Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases.

Vaidhyanathan S, Mittapalli RK, Sarkaria JN, Elmquist WF.

Drug Metab Dispos. 2014 Aug;42(8):1292-300. doi: 10.1124/dmd.114.058339. Epub 2014 May 29.

6.

Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.

Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF.

J Pharmacol Exp Ther. 2013 Mar;344(3):655-64. doi: 10.1124/jpet.112.201475. Epub 2012 Dec 17.

7.

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).

Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF.

J Pharmacol Exp Ther. 2012 Jul;342(1):33-40. doi: 10.1124/jpet.112.192195. Epub 2012 Mar 27.

8.

Selection of peptide ligands for human placental transcytosis systems using in vitro phage display.

Basha S, Vaidhyanathan S, Pauletti GM.

Methods Mol Biol. 2011;716:141-56. doi: 10.1007/978-1-61779-012-6_8.

PMID:
21318904

Supplemental Content

Loading ...
Support Center